https://scholars.lib.ntu.edu.tw/handle/123456789/525500
標題: | Mycoplasma pneumoniae in pediatric patients: Do macrolide-resistance and/or delayed treatment matter? | 作者: | Yang T.-I. Chang T.-H. CHUN-YI LU JONG-MIN CHEN PING-ING LEE LI-MIN HUANG LUAN-YIN CHANG |
公開日期: | 2019 | 出版社: | Elsevier Ltd | 卷: | 52 | 期: | 2 | 起(迄)頁: | 329-335 | 來源出版物: | Journal of Microbiology, Immunology and Infection | 摘要: | Background: Mycoplasma pneumoniae is a common pathogen for pneumonia in children, especially in the post-pneumococcal conjugate vaccination era. Though self-limited disease was found in the majority of the patients, severe diseases occurred occasionally. The emergence of macrolide resistance was reported worldwide. It is important to delineate whether macrolide resistance or delayed treatment affects outcome. Methods: We retrospectively collected pediatric patients with M. pneumoniae infection confirmed by positive PCR in a tertiary medical center in Taiwan from 2010 to 2017. Patients’ clinical characteristics, bacterial load, macrolide resistance and treatment outcome were analyzed. Results: Among 471 children with positive M. pneumoniae PCR, 95% were diagnosed with pneumonia. Seventeen percent of patients had extrapulmonary complications, and 1.5% had respiratory failure. Delayed treatment was associated with prolonged fever after appropriate treatment, fulminant disease, and extrapulmonary manifestations (p < 0.05). The mean rate of macrolide resistance was 24% and macrolide resistance was related to longer febrile duration, longer hospital stay, lung consolidation and impaired liver function tests (P < 0.05). Conclusions: Macrolide resistance was fairly common and might lead to delayed appropriate antibiotic treatment. Delayed appropriate antimicrobial treatment, no matter macrolide resistance or not, was associated with more severe and/or prolonged diseases. Early diagnosis of M. pneumoniae as well as the awareness of macrolide resistance make early effective antibiotic treatment possible and may improve clinical outcomes. ? 2018 |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85054785553&doi=10.1016%2fj.jmii.2018.09.009&partnerID=40&md5=68527e6164412fdd73c3c55804e17332 https://scholars.lib.ntu.edu.tw/handle/123456789/525500 |
ISSN: | 1684-1182 | DOI: | 10.1016/j.jmii.2018.09.009 | SDG/關鍵字: | alanine aminotransferase; aspartate aminotransferase; C reactive protein; macrolide; quinolone derivative; RNA 23S; tetracycline; antiinfective agent; macrolide; antibiotic therapy; Article; bacterial load; child; clinical feature; disease association; disease duration; female; fever; hospitalization; human; length of stay; liver function test; lung complication; macrolide resistance; major clinical study; male; Mycoplasma pneumonia; Mycoplasma pneumoniae; pediatric patient; pneumonia; polymerase chain reaction; respiratory failure; retrospective study; Taiwan; tertiary health care; therapy delay; treatment indication; treatment outcome; adolescent; antibiotic resistance; drug effect; genetics; hospital; infant; microbiology; mixed infection; Mycoplasma pneumonia; Mycoplasma pneumoniae; newborn; pathogenicity; pneumonia; preschool child; tertiary care center; time to treatment; Adolescent; Anti-Bacterial Agents; Bacterial Load; Child; Child, Preschool; Coinfection; Drug Resistance, Bacterial; Female; Fever; Hospitals; Humans; Infant; Infant, Newborn; Macrolides; Male; Mycoplasma pneumoniae; Pneumonia; Pneumonia, Mycoplasma; Polymerase Chain Reaction; Retrospective Studies; Taiwan; Tertiary Care Centers; Time-to-Treatment; Treatment Outcome |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。